Opus Genetics, Inc.

As of June 30, 2026, Opus Genetics, Inc. carries a market capitalization of 297.53M, placing it among publicly traded companies globally. Its enterprise value stands at 251.48M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Opus Genetics, Inc.'s next confirmed earnings release is scheduled for November 17, 2026.

As of June 30, 2026, Opus Genetics, Inc. has 82.65M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 33.69, and the price-to-book ratio stands at -26.18.

These figures are as of June 30, 2026. The EV/Sales ratio of 29.15 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 251.48M versus a market cap of 297.53M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Opus Genetics, Inc. maintains a current ratio of 12.19, meaning it holds 12.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -278.79, indicating conservative leverage, while an interest coverage ratio of -19.09 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -163.50, reflecting losses generated across the asset base. The company generates approximately 338,312.03 in revenue per employee across its workforce of 25.50, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Opus Genetics, Inc.'s stock has gained approximately 108.63% over the past 52 weeks. The 50-day moving average sits at 3.97, while the 200-day moving average is 3.59.

Over the twelve months ended June 30, 2026, Opus Genetics, Inc. generated 8.63M in revenue and converted that into -94.19M in net income, yielding earnings per share of -1.11. EBITDA reached -44.25M, while operating income came in at -44.30M.

As of June 30, 2026, Opus Genetics, Inc. holds 77.74M in cash and equivalents against 31.69M in total debt, resulting in a net debt position of -46.05M. Total book value stands at -11.37M, with working capital of 74.48M providing operational flexibility.

Opus Genetics, Inc. produced -35.60M in operating cash flow over the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The operating margin of -513.47 and net profit margin of -1,091.82 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -11.67: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -28.58, meaning Opus Genetics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Opus Genetics, Inc.'s most recent stock split took place on November 9, 2020 with a 4:1 split ratio.

As of June 30, 2026, Opus Genetics, Inc. has an Altman Z-Score of -2.62, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.